Progesterone receptors as a prognostic factor in Stage II breast cancer.
about
TReP-132 controls cell proliferation by regulating the expression of the cyclin-dependent kinase inhibitors p21WAF1/Cip1 and p27Kip1The progesterone receptor gene maps to human chromosome band 11q13, the site of the mammary oncogene int-2Young age: an independent risk factor for disease-free survival in women with operable breast cancerFrom bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?Synthesis, characterization and in vitro study of biocompatible cinnamaldehyde functionalized magnetite nanoparticles (CPGF Nps) for hyperthermia and drug delivery applications in breast cancerBreast cancer pathology, receptor status, and patterns of metastasis in a rural Appalachian populationInferring gene dependency network specific to phenotypic alteration based on gene expression data and clinical information of breast cancerSex steroid receptors in intracranial tumors.Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcomeHITS-CLIP reveals key regulators of nuclear receptor signaling in breast cancerProgesterone receptor variants found in breast cells repress transcription by wild-type receptors.Cloning of the chicken progesterone receptor.Estrogen and progesterone receptors in cytology: a comprehensive review.Progestin regulation of insulin and insulin-like growth factor I receptors in cultured human breast cancer cells.Feline mammary carcinoma: a retrospective evaluation of 17 casesMultidimensional chromatographic separation of estrogen receptors.Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors.Immunocytochemical staining of progesterone receptor in paraffin sections of human breast cancers.Role of the progesterone receptor (PR) in the regulation of inflammatory response pathways and aromatase in the breast.Growth fractions and estrogen receptors in human breast cancers as determined in situ with monoclonal antibodies.The association between vitamin D receptor expression and prolonged overall survival in breast cancer.PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptorsA prognostic score in histological node negative breast cancer.Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpressionOestrogen and progesterone receptors and disease-free interval in primary breast cancer.The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breastThe human tumour cloning assay in the management of breast cancer patients.Triple-negative breast cancer and obesity in a rural Appalachian population.The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer.Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimizationAltered expression of exon 6 deleted progesterone receptor variant mRNA between normal human breast and breast tumour tissues.Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women.Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancerIn situ Protein Detection for Companion Diagnostics.Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients.Oral contraceptives and breast cancer. Review and meta-analysis.Endocrine therapy of metastatic breast cancer.Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change afImmunohistochemical detection of progesterone receptors in archival breast cancer.
P2860
Q24529076-860A5711-DC4F-4A4D-A262-4AD7C1085D7DQ24610937-B5D288F4-A879-4A81-A7C2-91C8F2C63579Q24791855-9F14459B-DB86-4F38-A672-F358AF138750Q28084982-EE8CA2EB-970E-4AEF-B7A2-C0CB9BBA9001Q28543393-F72A687B-0CB0-41E9-9ABE-6FF55379C87BQ29006708-79F7F236-2EC8-4ADA-8339-BAD8D2BC81D6Q30000682-9C908227-7D88-4597-95D7-BDBEE6F2506BQ33274813-F8D84E37-1F9F-4840-9D6D-4F0B1F908568Q33745113-55444F34-E575-48F9-9221-CE77FB1E97CEQ33970563-CBFC6DA0-8B08-4DD1-BF45-0085678E0813Q34469025-0AA57789-0B87-4914-8FFE-489813B0BD8DQ35050960-BDDEE2CC-6B3D-40DC-8DF0-5BA8F7E9162FQ35374145-174E6989-A54C-462C-9315-BF42B4CC38A9Q35465155-CC5F3F21-6903-4F94-B178-B7026AE3E7D4Q35622853-AC145DA9-05E5-4B9E-9FFD-B683EBD5637DQ35706148-9FF4CAC5-8607-48B1-9B7A-8BF42B807EC7Q35774089-BF571B51-19A2-4467-98BF-7CBCE468BE55Q35816773-9E882357-C876-4A28-99F4-419AC366711AQ35839056-3EE757B2-76BB-431A-8EA4-349D79B716A4Q35856539-BBEF4591-EE59-425E-BF17-E63FAD8FDA76Q35955890-40FBCD7B-08DE-4766-9F9A-BCD6CBE10E27Q35977131-9090A5DA-7DA8-49E3-A395-09E21D10A72CQ35978394-50317B89-0420-4BF0-97F0-4B0CC28D5E25Q35981362-F38E9613-975C-4765-BF10-1A1F6D1423E1Q35981979-BCC45F28-D51A-41B2-8323-FE55740CB2D2Q35991972-881C64EF-23AC-425B-AD61-B3E7C1A58315Q35992143-A85FC4AD-636E-45C6-82AE-BEBC83CA6830Q35992302-D914AB20-629A-48A9-A0A2-A671E840E232Q36333924-E23371D9-1342-42CB-9071-5AB2AC4EDC2CQ36449060-DB61C3E5-E101-4B7A-BBB7-23F8C1995D3DQ36467712-49945FFA-37A4-478F-BC1C-5919B8E3A91DQ36617807-3D050804-68E2-46EC-951D-A8BCAC096529Q36619003-377BFFD5-5556-46EB-8824-0A402D107CD3Q37248242-BA321381-0B85-4242-B398-E4EDA41B83D2Q37270405-1DB731E5-212B-4A44-9C8A-E64EEB678DE1Q37639114-38989E26-AB1F-419E-9BA7-E36FAC8D3A9EQ37862481-286D4956-AD8A-4ED6-9218-FC025C65E7A2Q38363146-AA827719-F835-46AD-B97A-969D73F7ABBBQ38411841-E739E549-0196-40BC-97D4-7E613B35D010Q38471530-AE42B6F0-7613-41AB-A42D-D6A9A0A59332
P2860
Progesterone receptors as a prognostic factor in Stage II breast cancer.
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年論文
@yue
1983年論文
@zh-hant
1983年論文
@zh-hk
1983年論文
@zh-mo
1983年論文
@zh-tw
1983年论文
@wuu
1983年论文
@zh
1983年论文
@zh-cn
name
Progesterone receptors as a prognostic factor in Stage II breast cancer.
@en
type
label
Progesterone receptors as a prognostic factor in Stage II breast cancer.
@en
prefLabel
Progesterone receptors as a prognostic factor in Stage II breast cancer.
@en
P2093
P1476
Progesterone receptors as a prognostic factor in Stage II breast cancer.
@en
P2093
P304
P356
10.1056/NEJM198312013092240
P407
P577
1983-12-01T00:00:00Z